News for KTOV Stock

Kitov Announces Name Change to Purple Biotech Ltd. Kitov Pharma to Participate in November Investor Conferences Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219 New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24 and NT219 Kitov Pharma Announces ADS Ratio Change Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients Kitov Pharma Issues CEO Shareholder Letter Providing Business Update Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody Kitov Closes $35.0 Million Registered Direct Offering